Carlsmed (NASDAQ:CARL) Stock Rating Upgraded by Wall Street Zen

Carlsmed (NASDAQ:CARL) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other research analysts also recently commented on CARL. Truist Financial restated a “buy” rating and set a $20.00 price objective (up from $18.00) on shares of Carlsmed in a research note on Friday, November 7th. BTIG Research boosted their price target on shares of Carlsmed from $21.00 to $24.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Weiss Ratings initiated coverage on shares of Carlsmed in a research report on Thursday, October 16th. They set a “sell (e)” rating for the company. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Carlsmed has an average rating of “Hold” and an average price target of $22.00.

Carlsmed Stock Up 3.1%

NASDAQ CARL opened at $13.11 on Friday. Carlsmed has a one year low of $11.76 and a one year high of $16.20. The firm has a 50-day simple moving average of $13.51.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05. Carlsmed has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Carlsmed

A number of institutional investors and hedge funds have recently bought and sold shares of CARL. Burkehill Global Management LP acquired a new position in shares of Carlsmed in the 3rd quarter worth approximately $670,000. Orbimed Advisors LLC acquired a new stake in Carlsmed during the third quarter valued at approximately $16,772,000. Ghisallo Capital Management LLC acquired a new stake in Carlsmed during the third quarter valued at approximately $670,000. Boston Partners bought a new stake in Carlsmed during the third quarter worth approximately $393,000. Finally, BNP Paribas Financial Markets acquired a new position in Carlsmed in the third quarter worth approximately $33,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).